SEARCH

SEARCH BY CITATION

References

  • Awad A., Hemmer B., Hartung H. P., Kieseier B., Bennett J. L. and Stuve O. (2010) Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J. Neuroimmunol. 219, 17.
  • Becker K. G., Mattson D. H., Powers J. M., Gado A. M. and Biddison W. E. (1997) Analysis of a sequenced cDNA library from multiple sclerosis lesions. J. Neuroimmunol. 77, 2738.
  • Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F. and Reindl M. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 349, 139145.
  • Black J. A., Newcombe J. and Waxman S. G. (2010) Astrocytes within multiple sclerosis lesions upregulate sodium channel Nav1.5. Brain 133, 835846.
  • Brettschneider J., Tumani H., Kiechle U., Muche R., Richards G., Lehmensiek V., Ludolph A. C. and Otto M. (2009) IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS ONE 4, e7638.
  • Cavone L. and Chiarugi A. (2012) Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis? Trends Mol. Med. 18, 92100.
  • Cleutjens K. B., Faber B. C., Rousch M. et al. (2008) Noninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling. J. Clin. Invest. 118, 29792985.
  • Evsyukova I., Somarelli J. A., Gregory S. G. and Garcia-Blanco M. A. (2010) Alternative splicing in multiple sclerosis and other autoimmune diseases. RNA Biol. 7, 462473.
  • Fredrikson S., Baig S. and Link H. (1991) Immunoglobulin producing cells in bone marrow and blood of patients with multiple sclerosis and controls. J. Neurol. Neurosurg. Psychiatry 54, 412414.
  • Freedman M. S., Laks J., Dotan N., Altstock R. T., Dukler A. and Sindic C. J. (2009) Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult. Scler. 15, 422430.
  • Freedman M., Metzig C., Kappos L. et al. (2011) Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult. Scler. 18, 966973.
  • Govarts C., Somers K., Hupperts R., Stinissen P. and Somers V. (2007) Exploring cDNA phage display for autoantibody profiling in the serum of multiple sclerosis patients: optimization of the selection procedure. Ann. N. Y. Acad. Sci. 1109, 372384.
  • Govarts C., Somers K., Hupperts R., Stinissen P. and Somers V. (2009) Analysis of antibody reactivity in paired cerebrospinal fluid and serum of a relapsing remitting multiple sclerosis patient. Autoimmunity 42, 699704.
  • Hauser S. L., Waubant E., Arnold D. L. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676688.
  • Hufton S. E., Moerkerk P. T., Meulemans E. V., de Bruine A., Arends J. W. and Hoogenboom H. R. (1999) Phage display of cDNA repertoires: the pVI display system and its applications for the selection of immunogenic ligands. J. Immunol. Methods 231, 3951.
  • Kuhle J., Pohl C., Mehling M. et al. (2007) Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 356, 371378.
  • Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M. and Lassmann H. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707717.
  • Lunemann J. D. and Ascherio A. (2009) Immune responses to EBNA1: biomarkers in MS? Neurology 73, 1314.
  • Mahajan S. S., Little M. M., Vazquez R. and Wilson A. C. (2002) Interaction of HCF-1 with a cellular nuclear export factor. J. Biol. Chem. 277, 4429244299.
  • Masjuan J., Alvarez-Cermeno J. C., Garcia-Barragan N., Diaz-Sanchez M., Espino M., Sadaba M. C., Gonzalez-Porque P., Millan Martinez San and J. and Villar, L. M. (2006) Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 66, 576578.
  • Mathey E. K., Derfuss T., Storch M. K. et al. (2007) Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 204, 23632372.
  • McDonald W. I., Compston A., Edan G. et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121127.
  • Miller D., Barkhof F., Montalban X., Thompson A. and Filippi M. (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 4, 281288.
  • Ng B., Yang F., Huston D. P., Yan Y., Yang Y., Xiong Z., Peterson L. E., Wang H. and Yang X. F. (2004) Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J. Allergy Clin. Immunol. 114, 14631470.
  • Obermeier B., Mentele R., Malotka J., Kellermann J., Kumpfel T., Wekerle H., Lottspeich F., Hohlfeld R. and Dornmair K. (2008) Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med. 14, 688693.
  • Otto C., Oltmann A., Stein A., Frenzel K., Schroeter J., Habbel P., Gartner B., Hofmann J. and Ruprecht K. (2011) Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis. Neurology 76, 13161321.
  • Owens G. P., Burgoon M. P., Devlin M. E. and Gilden D. H. (1996) Strategies to identify sequences or antigens unique to multiple sclerosis. Mult. Scler. 2, 184194.
  • Pohl D., Rostasy K., Jacobi C., Lange P., Nau R., Krone B. and Hanefeld F. (2010) Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J. Neurol. 257, 212216.
  • Polman C. H., Reingold S. C., Edan G. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58, 840846.
  • Rovaris M., Confavreux C., Furlan R., Kappos L., Comi G. and Filippi M. (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 5, 343354.
  • Soares M. B., Bonaldo M. F., Jelene P., Su L., Lawton L. and Efstratiadis A. (1994) Construction and characterization of a normalized cDNA library. Proc. Natl Acad. Sci. USA 91, 92289232.
  • Somers V. A., Brandwijk R. J., Joosten B. et al. (2002) A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J. Immunol. 169, 27722780.
  • Somers V., Govarts C., Hellings N., Hupperts R. and Stinissen P. (2005) Profiling the autoantibody repertoire by serological antigen selection. J. Autoimmun. 25, 223228.
  • Somers V., Govarts C., Somers K., Hupperts R., Medaer R. and Stinissen P. (2008) Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. J. Immunol. 180, 39573963.
  • Somers K., Stinissen P. and Somers V. (2009) Optimization of high-throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1173, 92102.
  • Somers K., Geusens P., Elewaut D., De Keyser F., Rummens J. L., Coenen M., Blom M., Stinissen P. and Somers V. (2011) Novel autoantibody markers for early and seronegative rheumatoid arthritis. J. Autoimmun. 36, 3346.
  • Steinberg S. J., Dodt G., Raymond G. V., Braverman N. E., Moser A. B. and Moser H. W. (2006) Peroxisome biogenesis disorders. Biochim. Biophys. Acta 1763, 17331748.
  • Szmyrka-Kaczmarek M., Pokryszko-Dragan A., Pawlik B., Gruszka E., Korman L., Podemski R., Wiland P. and Szechinski J. (2011) Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus.
  • Tomassini V., De Giglio L., Reindl M., Russo P., Pestalozza I., Pantano P., Berger T. and Pozzilli C. (2007) Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult. Scler. 13, 10861094.
  • Villar L. M., Sadaba M. C., Roldan E. et al. (2005) Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 115, 187194.
  • Xiao Q., Hartzell H. C. and Yu K. (2010) Bestrophins and retinopathies. Pflugers Arch. 460, 559569.
  • Zephir H., Lefranc D., Dubucquoi S., de Seze J., Boron L., Prin L. and Vermersch P. (2009) Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis. Mult. Scler. 15, 593600.
  • Zhou D., Srivastava R., Nessler S., Grummel V., Sommer N., Bruck W., Hartung H. P., Stadelmann C. and Hemmer B. (2006) Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl Acad. Sci. USA 103, 1905719062.